Home -> Law Blog Directory -> Patent Law Blogs -> Patently Obvious
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Patent Law
: Patently ObviousCalculating PTA: PTO to offer "guidance for expediting requests."
By Dennis Crouch, Esq.
The USPTO has announced it will not seek further review of the Wyeth v. Kappos decision. In that case, the Federal Circuit held that the USPTO has been under-calculating the Patent Term Adjustment (PTA) owed to patentees based on USPTO prosecution delays. In its announcement, the USPTO indicated that is 'preparing guidance for expediting requests for recalculation of patent term adjustments by the USPTO in light of the Wyeth decision.'
Although I have not completed the calculations, the patents perhaps most-likely to have some additional patent-term due to the Wyeth decision are those whose prosecution history include both (1) a pendency (not counting priority) of more than three years before either the patent issues or the applicant files an RCE and (2) a delay of more than 14–months from the application filing to the mailing of the first examination 'notification.' Notifications that qualify include a Notice of Allowance, Final or Non-Final Rejection, Restriction Requirement, and an Ex Parte Quayle Action. Pre-examination notices such as a notice of omitted items or notice of incomplete application typically do not satisfy the PTO's duty of meeting the 14–month deadline. Before Wyeth, the PTO treated the beyond-three-year-issuance delay as overlapping with the the beyond-14–month-notification delay. That is no longer the case.
In a random sample of 674 patents issued in the past year and filed after May 2000, I found that 479 (71%) both (1) had a pendency (smaller of filing-to-RCE and filing-to-Issuance) of greater than three years and also (2) had not received a qualifying notification with 14–months. Although I cannot say this with certainty yet, I believe that most of these newly issued patents deserve additional patent term under the Wyeth decision.
Full post as published by Patently Obvious on January 25, 2010 (boomark / email).
American Express
allegedly failed to properly inform customers of Blue Cash credit card offer components.
FDA
Requests Labeling Change for Singulair, Accolate and Zyflo and Zyflo CR

ICO guidance on vexatious requests updated
USPTO and DOJ Will Not Seek Review of Wyeth v. Kappos
Obtaining Staff Guidance: No-Action, Interpretive and Exemptive Requests
DOJ Issues New Guidances on FOIA Requests, Fees, Response Time







